IP Regime With Respect To Access To Health Care In Public Health Emergencies

Lives have moved ahead a million squares in the time span of a few decades. Advancement of  Science and Technology has revealed a new essence to the world. However, even though progress in all spheres has greatly improved the quality of human life, certain ancillary outcomes have been highly undesirable. In a rat race of establishing a set system of governance for every probable issue, the question as to who actually is the beneficiary has been greatly neglected. One of the most prominent examples of such a dichotomy is the grant of patents for pharmaceuticals and the Right to access Healthcare. The issue has further gained more prominence especially with the emergence of COVID 19 as a heath pandemic. The very obvious questions which needs consideration here relates to the fact that COVID has claimed more than over 2 million lives globally with only a handful of countries being able to successfully manufacture a efficient and effective vaccine. So, the dichotomy is very evident in terms of whether the patent protection is to prevail over the right to access public health.

[Picture Credit: gettyimage]covid

The recent time has witnessed a huge boom in the commercialisation of pharmaceuticals which has ultimately led the companies to get their products patented, i.e., to get their products protected from copying by rival companies under the intellectual Property laws. The recent time has also not been vary to the invention of novel varities of drug which can be used to cure such medical infirmities that were almost incurable earlier. In a layman’s terms, let us understand it this way that it is a of course a boon to mankind but every good thing comes at a cost. In more precise terms, when a pharmaceutical company comes up with any drug, the first thing it does is to seek protection for its invention so that other rival companies do not copy their hard earned formulas.

Under the present circumstances, patent can be considered as the most used as well as abused Intellectual property. On the one hand patents can be considered a reward or an incentive for the creativity and hard work and work as a motivation for the companies to invest more in R&D but on the other hand it might also lead to an abuse by the patent holder in the sense that  at times it may lead to monopolistic tendencies. When a company gets a patent over a drug it in a way gets the authority to regulate the price of that particular drug. So, if the price of any drug is kept very high only a few people would be in a position to afford that particular drug.

Our constitution guarantees right to health as fundamental right under Article 21. Hence, a balance is to be drawn between such fundamental right and such pharmaceutical patent so that there is no conflict of interest between any of the stakeholders involved.

The Apex Court in the case of All India drug action network v. Union of India Ministry of Health  has also held that the government should take steps to ensure timely access to lifesaving drugs for its citizens. As a corollary to the above mentioned propositions, the Ayyaangar committee report on patents also bought forth the observation that there is a high risk factor involved when it comes to granting of patents in a country like India. The patents confer monopolistic rights which in a way are against the interest of majority of population which is poor. This will be against the notion of access to medicines. The report also stated that any policy which has character of granting monopoly right is violative of preamble and also the Article 21 of our constitution.

TRIPS

When the Trade related aspects of Intellectual Property Rights (TRIPS) Agreement came into force it worked as an encouragement for the private players in the market but the situation was significantly different prior to emergence of the TRIPS agreement. It is pertinent to note here that the patents Act, 1970 only granted patent on the process and not on the product because of which there was a rapid growth in the development of generic drugs at that point of time. So, the domestic players could very conveniently reproduce and market the new drugs because all that they had to do was to merely change the process of production. With this trend, the pharmaceutical industry could manage to cater to the needs of the lower strata of the society by producing lifesaving and essential drugs at a fairly lower cost.

Thus, we see that the pre TRIPS era of granting patents, specifically, was comparatively less stringent and was also helpful in regulating monopolistic activities by setting the price in a way so as to be within the reach of the poorer strata of the society as well.

COMPULSORY LICENSING

Compulsory Licensing is a procedure through which, any company, agency or person can use

or manufacture a patented product without taking the consent from the patent-holder. Under the International regime, a country with “insufficient capabilities” can make use of compulsory licensing in order to copy the formula developed by other countries to produce the medicines locally. Such an authorisation is given by the Controller general under the Indian Regime. Compulsory licensing not only finds a mention under the TRIPS Agreement but also under the Indian Patents Act, 1970. Additionally, there is a prescribed time frame of three years before which a private entity cannot apply for compulsory licensing. However, a national emergency falls as an exemption to this stated statutory prescription and the government has special powers to bypass such a time stipulation. Sec 84 of the Act requires certain conditions to be met before a compulsory license can be granted:

  1. Public requirements associated with the patented product must not be satisfied;
  2. The price of the invention must not be affordable;
  3. The invention is not worked in the territory of India.

A textbook example of the use of Compulsory License has been for the domestic production of COVID 19 vaccines by the under developed and the developing countries. There being an acute shortage of vaccines and the lives of millions of people at stake, Compulsory Licensing has come at rescue for many countries.

The bid to balance the need of Pharmaceutical MNCs to have well protected product patents and the needs of India’s healthcare system which caters to a diverse population comprising majorly of the below poverty line section, has been a constant struggle. Up until 2005, the laws in India were lenient and allowed for copycat products, which helped in flourishing India’s Pharmaceutical industry. However, to keep pace with the changing society, the laws also need to change accordingly. This is precisely why India introduced Amendments if its Patent Act in 2005 to keep pace with the changes brought in by the TRIPS Agreement.

When we talk specifically about the COVID 19 crisis, vaccine diplomacy and vaccine nationalism are the most important concerns. Under such a backdrop, the importance of international collaboration needs to be understood. The global capacity for producing vaccines is around 3.5 billion while 10 billion is the required minimum thresh hold.

In the wake of such emergency India and eight other countries have proposed to exempt vaccines from patents and other forms of IPR.

The patents of various pharmaceutical companies act as an impediment to the amplification and production of vaccines. It is pertinent to note that Moderna alone has 12 patents on their mRNA vaccine. The world health organization does not have the authority to sidestep patents

but it is trying to bring countries together to find a way to bolster vaccine supplies. While the larger view has been that patent protection for vaccines can have an adverse impact on the under developed and developing countries since they neither have the resources nor the know how to be self-sufficient,  arguments have also been made that “eliminating those protections would undermine the global response to the pandemic including ongoing efforts to tackle new variants and would ultimately undermine public confidence towards vaccine safety and create a barrier to information sharing. Thus, most importantly, eliminating protections would not speed up the production process anyways.”

There have also been cases wherein technology transfer based on voluntary license have been successfully granted. For instance, between AstraZeneca, Oxford and Serum Institute of India.

The robust regime of IPR in India in such cases should be effectively engaged and efficiently used as a tool to mitigate the disparity between private and public interest. In India, an essential prerequisite for the grant of patent is the royalty free use of a patented invention by the Central Government. In this regard, Section 92 of the Patents Act authorizes the Central Government to issue compulsory license at any time after the grant of Patent in case of a national emergency or extreme urgency. It is pertinent to note that the Coronavirus outbreak, under all circumstances, qualifies as a Public Health Emergency of International Concern and thus can be seen as a matter of national emergency or extreme urgency.  Section 102 of the Patents Act further gives the Central Government the power to acquire a patent from the patentee or the applicant if there is a national emergency. In this regard, adequate compensation shall be paid to the Patentee.

Thus, we see that while compulsory licensing may not be the most ideal way to deal with the current situation, it is definitely beneficial for breaking the patent impasse.

Conclusion:

The battle between the conflicting interests of developed and developing countries may continue for long as the complexities associated with the development of patent laws can take up uncountable suggestions, amendments and volumes.

Developing countries are often stuck between the obligation to comply with the global agreements and the duty to provide accessible healthcare to its citizens. India has covered a hue distance backwards where in Pre-TRIPS era, it had less stringent laws and allowed legal re-production of patented medicines as compared to the Post-TRIPS era, where it had to comply with TRIPS and subsequently had to illegalize this reverse engineering. However, needless to say, despite this India has maintained sufficient leniency in upholding the  right to health, as is evident from the current pandemic situation.

Here, what needs to be fathomed is that undeniably monetary interest of many big companies comes to stake when the price of a lifesaving drug is regulated but innovation and patents are the two different sides of the same coin. This coin needs to be flipped keeping in mind public health because ultimately innovations in pharmaceutical industry are meant to save lives.

Author: Mahak Agrawal – a student of Symbiosis Law School (Nagpur), in case of any queries please contact/write back to us via email chhavi@khuranaandkhurana.com or at IIPRD.

Leave a Reply

Your email address will not be published.

fourteen − 14 =

Archives

  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010